Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to $26687.0.

  • Bioadaptives' Change in Accured Expenses rose 7447.04% to $26687.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $60852.0, marking a year-over-year increase of 3376.42%. This contributed to the annual value of $44831.0 for FY2024, which is 1297.0% up from last year.
  • Per Bioadaptives' latest filing, its Change in Accured Expenses stood at $26687.0 for Q3 2025, which was up 7447.04% from $12265.0 recorded in Q2 2025.
  • Over the past 5 years, Bioadaptives' Change in Accured Expenses peaked at $109110.0 during Q3 2021, and registered a low of -$16222.0 during Q1 2021.
  • Over the past 5 years, Bioadaptives' median Change in Accured Expenses value was $12358.0 (recorded in 2025), while the average stood at $28774.4.
  • The largest annual percentage gain for Bioadaptives' Change in Accured Expenses in the last 5 years was 1128935.28% (2021), contrasted with its biggest fall of 18365.31% (2021).
  • Bioadaptives' Change in Accured Expenses (Quarter) stood at $107924.0 in 2021, then plummeted by 89.27% to $11575.0 in 2022, then decreased by 11.85% to $10203.0 in 2023, then decreased by 6.48% to $9542.0 in 2024, then surged by 179.68% to $26687.0 in 2025.
  • Its Change in Accured Expenses stands at $26687.0 for Q3 2025, versus $12265.0 for Q2 2025 and $12358.0 for Q1 2025.